Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high‐risk first relapse B‐cell precursor acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high‐risk first relapse B‐cell precursor acute lymphoblastic leukemia

Published:2022-04-28 Issue:8 Volume:69 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Locatelli Franco¹^ORCID,Eckert Cornelia²^ORCID,Hrusak Ondrej³,Buldini Barbara⁴,Sartor Mary⁵,Zugmaier Gerhard⁶^ORCID,Zeng Yi⁷,Pilankar Deepali⁸,Morris Joan⁷,von Stackelberg Arend²

Affiliation:

1. IRCCS Ospedale Pediatrico Bambino Gesù and Sapienza University of Rome Rome Italy

2. Charite–Universitatsmedizin Berlin Berlin Germany

3. Charles University, Motol University Hospital Prague Czech Republic

4. Maternal and Child Health Department University of Padua Padua Italy

5. Westmead Hospital Sydney New South Wales Australia

6. Amgen Research (Munich) GmbH Munich Germany

7. Amgen Inc. Thousand Oaks California USA

8. IQVIA Mumbai India

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29715

Reference11 articles.

1. Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group

2. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

3. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia

4. How I treat relapsed childhood acute lymphoblastic leukemia

5. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA;Mediterranean Journal of Hematology and Infectious Diseases;2024-08-31

2. Allogeneic Hematopoietic Cell Transplantation With Reduced Toxicity Conditioning for Pediatric B Lymphoid Malignancy;Journal of Pediatric Hematology/Oncology;2024-08-12

3. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults;New England Journal of Medicine;2024-07-25

4. Blinatumomab vs Chemotherapy for Pediatric and Adult Acute Lymphoblastic Leukemia;OBM Genetics;2024-07-19

5. Outcomes of children treated for relapsed or refractory acute lymphoblastic leukemia: A single tertiary care center experience;Cancer Reports;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3